Soleno Therapeutics (NASDAQ: SLNO) shares plummeted 21.39% in pre-market trading on Wednesday, following a sharp decline in after-hours trading on Tuesday. The significant drop comes as a surprise to many investors, given the company's strong third-quarter 2025 financial results released after the market close on Tuesday.

For the quarter ended September 30, 2025, Soleno reported impressive financial performance, including: - Revenue of $66.0 million - Net income of $26.0 million, or $0.47 per diluted share - Operating income of $22.1 million The company's earnings per share of $0.47 significantly beat the mean analyst expectation of $0.05. Soleno also highlighted the successful U.S. launch of VYKAT XR, its treatment for hyperphagia in patients with Prader-Willi syndrome (PWS), reporting 1,043 patient start forms received since the drug's approval in March 2025, with 764 active patients on the drug as of September 30.

Despite these seemingly positive results, the sharp decline in Soleno's stock price suggests that investors may have had even higher expectations or are concerned about other factors not immediately apparent in the headline numbers. Possible reasons for the sell-off could include: 1. Valuation concerns: The stock may have been priced for perfection, and even strong results couldn't justify its current valuation. 2. Future growth worries: Investors might be questioning the long-term growth potential of VYKAT XR or the company's pipeline. 3. Competitive landscape: There could be concerns about potential competition in the PWS treatment market. 4. Profit-taking: Some investors may be selling to lock in gains, as biotech stocks can be volatile following earnings releases. As the market continues to digest the full earnings report and management's commentary, it will be crucial to watch for any additional insights that might explain the stock's dramatic pre-market plunge.